Dear Erowid Readers: We're a small nonprofit that runs the top drug information website in the world. We have only 4 staff but serve 12 million users, and have costs like any big website: servers, power, office space, programs, and staff. To protect our independence, we don't run ads or take government funds. If everyone reading this gave $3, our fundraising would be done today. If Erowid is useful to you, take a minute to keep it online and ad-free another year!
Donate by Bitcoin

Erowid References Database

Feigenbaum JJ, Howard SG. 
“Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study”. 
Neurosci Lett. 1997 Mar 01;224(1):71-4.
gamma-Hydroxybutyrate (GHB) is a 4-carbon anesthetic that acts primarily by inhibiting presynaptic dopamine (DA) release in vivo. A number of studies have reported a reversal of many of the central effects of GHB by the allegedly pure opiate antagonist naloxone (NX) but its mechanism of action is unclear. In vivo microdialysis performed in the present preliminary study disclosed a significant inhibitory effect of GHB (500 mg/kg) on striatal DA release which was completely reversed by a low dose of NX (0.8 mg/kg). The results indicate that NX likely inhibits many of the central effects produced by GHB primarily through its reversal of the GHB induced inhibition of central DA release.
Submit Comment
[ Cite HTML ] Plants & Drugs Mind & Spirit Freedom & Law Arts & Sciences Search About Erowid and Feedback Library & Bookstore Copyrights Memberships noref